Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New
treatment options are becoming available, and there is a need to characterize the …

Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may
potentially identify both viral genotype and resistance genetic motifs in the era of directly …

Recent advances in hepatitis C virus (HCV) therapies have transformed the treatment
landscape for this disease. However, efficacy of current treatments depends on HCV …

More than 20million hepatitis C virus (HCV) carriers live in the countries of the Eastern
Mediterranean. We determined HCV genotype distribution among chronically infected …

BACKGROUND: Hepatitis C virus (HCV) is the foremost cause of deaths attributable
tocirrhosis and hepatocellular carcinoma. The Global Burden of Disease (GBD) study from …

Background Analysis of laboratory testing data collected through the Sentinel Surveillance
programme has provided a method for identifying individuals who have recently acquired …

Objectives: To estimate clinical outcomes and cost-effectiveness of ombitasvir/paritaprevir/
ritonavir and dasabuvir±ribavirin (OMB/PTV/r+ DSV±RBV) compared with treatment …

CD8+ T‐cell responses to hepatitis C virus (HCV) are important in generating a successful
immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) …

The infection with more than one hepatitis C virus (HCV) genotype especially in subjects
with a high risk of multiple HCV exposures has been demonstrated. The role of HCV mixed …

The distribution of HCV genotypes among injection drug users in Hong Kong was assessed
in context of methadone treatment availability. Three time periods were defined by the year …